Compare EPAM Systems Inc (EPAM) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPAM Systems Inc vs Nuwellis Inc — how do they compare? EPAM Systems Inc trades at $112.92 (market cap $5.87B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: EPAM Systems Inc is far larger — about 2668.2× Nuwellis Inc's market cap, and EPAM Systems Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold EPAM Systems Inc for 37 Days and Nuwellis Inc for 26 Days on average.
| EPAM | NUWE | |
|---|---|---|
Market Cap | $5.87B | $2.20M |
Volume | 847,420 | 121,544 |
Sector | Technology | Health |
52-Week High | $221.40 | $146.65 |
52-Week Low | $76.04 | $0.68 |
Typical Hold Time | 37 Days | 26 Days |
Enterprise Value | $5.24B | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPAM Systems trades at $113.54, up 4.82% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a consensus price target of $119 suggest upside potential. The company reported $5.46B in 2025 revenue, with a net income margin of 7.15%, while maintaining solid cash flow from operations of $654.93M.
The outlook is positive, driven by AI-native revenue growth exceeding 11% and activist shareholder pressure for buybacks. Risks include slower North American growth and competitive pressures in digital transformation services. The stock's current valuation at a P/E of 15.45 appears reasonable relative to earnings growth prospects.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
